

### Investment Objective

Foresight 4 VCT plc is a Venture Capital Trust aiming to provide investors with attractive returns from a portfolio of investments in fast growing, unquoted UK companies.

### Performance Summary

**57.2p**


NAV per Share  
(as at 30 June 2020)

**2.8p**

Dividend per Share  
(paid 28 August 2020)

The NAV per share increased 2.5% over the period from 55.8p at 31 March 2020 to 57.2p at 30 June 2020.

### Foresight 4 VCT plc Total Returns vs FTSE AIM All Share (rebased)




### Top 10 Investments

Position	Company	% NAV
1	Datapath Group Limited	13%
2	Specac International Limited	6%
3	TFC Europe Limited	5%
4	Ixaris Group Holdings Limited	4%
5	FFX Group Limited	4%
6	Innovation Consulting Group	3%
7	Protean Software Limited	3%
8	Aerospace Tooling Corporation Limited	2%
9	Biofortuna Limited	2%
10	Hospital Services Group Limited	2%

### Sector Weightings

% by value



### Portfolio Activity

Due to the unprecedented environment resulting from the COVID-19 virus outbreak, The Company has not made any new or follow-on investments during the first half of 2020. However, some Investee Companies have been contributing to the national efforts to defeat the virus:

#### Hospital Services Ltd (HSL)

HSL adapted quickly at the start of the pandemic and joined in the national efforts to help defeat COVID-19 through procuring PPE. With a customer base and supply chain now in place for PPE, HSL will continue to provide these products for the foreseeable future. Separate to this new revenue stream, HSL has also seen increased demand for mobile x-ray machines, as chest x-rays are part of the treatment pathway for COVID-19.



#### Biofortuna

Biofortuna has been a key partner for companies bringing PCR test kits to market to detect the virus. With the significant historical investment in manufacturing capacity and capability, Biofortuna was well positioned to support development and manufacture of clients COVID-19 tests. To date, they have manufactured over 17.5m test kits.



#### Mologic

Following a high-profile visit from Prime Minister, Boris Johnson, Mologic received a grant of c.£1m from the UK Government's £46m package towards finding a vaccination and developing a rapid test for COVID-19. Since March, the business has developed and distributed COVID-19 diagnostic kits globally.



### Key Information

Launch Date	1998
Foresight Takeover Date	2004
Net Assets (£'000)	111,048
Share Price per share	50.0p
NAV per share	57.2p
Premium/Discount to NAV	(12.6%)
Total Expense Ratio (TER)	2.4%
Total Return for 1 year (re-based)	(10.4%)
Total Return for 3 years (re-based)	(5.4%)
Total Return for 5 years (re-based)	(8.7%)
Movement in NAV (since last quarter)	2.5%
No. of Investee Companies	32
Annual Management Charge (AMC)	2.0%
Secretarial Charge	0.3%
ISIN Code	GB00B07YBS95
SEDOL Code	B07YBS9
Year End	31 March
Annual Report & Accounts Published	July

### Definitions

NAV	Net Asset Value
TMT	Technology, Media & Telecommunications

### Meet the Board

#### Raymond Abbott (Chairman)

Previously the Managing Director of Alliance Trust Equity Partners. Chairman of the Scottish Building Society and independent non-executive Director of Woodford Patient Capital Trust PLC.

#### Simon Jamieson

Simon spent his career in asset management, principally with FF&P Asset Management Ltd.

#### Michael Gray

Formerly Chairman for RBS Corporate Bank and Regional Manager Director, Corporate Banking, RBS International.

#### Gaynor Coley

Gaynor is a qualified Chartered Accountant with over 30 years of experience in private and public sector finance and governance. Gaynor is also chair of the audit committee on a variety of listed investment trusts.

### About Foresight Group

Foresight Group is a leading independent infrastructure and private equity investment manager which has been managing investment funds on behalf of institutions and retail clients for more than 35 years. Foresight is headquartered in London, with international offices in Seoul, Rome, Madrid and Sydney and regional UK offices in Nottingham, Manchester, Leicester, Milton Keynes, Guernsey, Edinburgh & Cambridge.



**900 years'**

combined Investment  
experience across a  
wide range of sectors



**c.£6.5bn**

of assets under  
management

### Portfolio Managers

**Russell Healey**

[rhealey@foresightgroup.eu](mailto:rhealey@foresightgroup.eu)

**James Livingston**

[jlivingston@foresightgroup.eu](mailto:jlivingston@foresightgroup.eu)

**Matthew Smith**

[msmith@foresightgroup.eu](mailto:msmith@foresightgroup.eu)

**Claire Alvarez**

[calvarez@foresightgroup.eu](mailto:calvarez@foresightgroup.eu)

**Rodney Appiah**

[rappiah@foresightgroup.eu](mailto:rappiah@foresightgroup.eu)

#### For further information contact Foresight:

The Shard, 32 London Bridge Street, London, SE1 9SG

T: +44 (0)20 3667 8181

E: [investorrelations@foresightgroup.eu](mailto:investorrelations@foresightgroup.eu)

[www.foresightgroup.eu/retail-investors/retail-investor-relations/](http://www.foresightgroup.eu/retail-investors/retail-investor-relations/)

**Important Notice** This document has been issued and approved by Foresight Group LLP, which is authorised and regulated by the Financial Conduct Authority. This document is intended for information purposes only and does not create any legally binding obligations on the part of Foresight Group LLP. Without limitation, this document does not constitute an offer, an invitation to offer or a recommendation to enter into any transaction. We recommend that you seek advice from your own tax and legal advisers in making this assessment. The information contained in this document is based on material we believe to be reliable. However, we do not represent that it is accurate, current, complete or error free. Assumptions, estimates and opinions contained in this document constitute our judgement as of the date of the document and are subject to change without notice. Past performance is not a guarantee of future results. The distribution of this document and availability of this product in certain jurisdictions may be restricted by law. You may not distribute this document, in whole or in part, without our express written permission. Capital at risk.